Slide 1: Immatics Corporate Presentation
© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation August 18, 2026 Exhibit 99.3
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective c
Slide 3: PRAME Is Expressed in More Than 50 Cancers
PRAME Is Expressed in More Than 50 Cancers Anzutresgene autoleucel (anzu-cel, formerly IMA203), 1 Data on file: PRAME target prevalence is based on a proprietary initial mass spec-guided expression threshold applied to RNAseq and/or IHC data (approximate values, values between 95-100% shown as 95%);
Slide 4: Immatics Is the Global Leader in Precision Targeting of PRAME
Immatics Is the Global Leader in Precision Targeting of PRAME PRAME is an intracellular protein presented as a peptide on the surface of tumor cells by HLA molecules1 The PRAME peptide can be targeted by T-cell receptors (TCRs) engineered by Immatics, thus overcoming limitations of classical antibod
Slide 5: Product candidate pipeline
Product candidate Modality Indication Target Anzu-cel (IMA203) Cell therapy 2L melanoma2 Anzu-cel (IMA203) Cell therapy Uveal melanoma Anzu-cel (IMA203) + mRNA-4203 Cell therapy Solid cancers IMA203CD8 Cell therapy Gynecologic cancers Other solid cancers IMA402 Bispecific Melanoma, gynecologic cance
Slide 6: PRAME Wave #2 and Wave #3 addressable patients
PRAME Wave #2 PRAME Wave #3 Anzutresgene autoleucel (anzu-cel, formerly IMA203), All patient numbers refer to PRAME+/HLA-A*02:01+ patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast; EU5: France, Germany, Italy, Spain, United Kingdom; a 2L: patients with unresectable
Slide 7: Broadest PRAME Franchise with Most PRAME Indications and Modalities
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities PRAME Wave #1 PRAME Wave #2 PRAME Wave #3 >230K addressable PRAME+/HLA-A*02:01+ patients in the US & EU5 p.a. Anzu-cel (IMA203) PRAME Cell Therapy IMA203CD8 PRAME Cell Therapy IMA402 PRAME Bispecific Ph1a data u
Slide 8: PRAME Target Product Profile (TPP)
PRAME 1 Target product profile (TPP) in monotherapy in 2L or later settings post SOC at recommended phase 2 dose (“RP2D”) for development beyond Ph1b. Other factors such as mPFS (median progression free survival) and mOS (median overall survival) may also be considered. SOC: standard of care LYMPHOD
Slide 9: Anzu-cel (IMA203) PRAME Cell Therapy Market Entry in Advanced Melanoma
Anzu-cel (IMA203) PRAME Cell Therapy Market Entry in Advanced Melanoma PRAME Wave #1 9 Anzutresgene autoleucel (anzu-cel, formerly IMA203)
Slide 10: Anzu-cel Market Entry in Advanced Melanoma
Anzu-cel (IMA203) PRAME Cell Therapy: Market Entry in Advanced Melanoma Anzu-cel (IMA203) Opportunity 2L Unresectable or Metastatic Cutaneous Melanoma* ~7.3K addressable PRAME+/HLA-A*02:01+ patients in the US & EU5 ~1.3K addressable PRAME+/HLA-A*02:01+ patients in the US & EU5 Anzutresgene autoleuce
Slide 11: Positive Data and High Unmet Need
Positive Data and High Unmet Need SUPRAME: Phase 3 randomized trial of anzu-cel vs. investigator choice in 2L cutaneous melanomad ongoing (#NCT06743126) Phase 2 single arm cohort of anzu-cel in metastatic uveal melanoma ongoing (#NCT03686124) Anzutresgene autoleucel (anzu-cel, formerly IMA203), a Ma
Slide 12: Ph 1b Study of Anzu-cel in Advanced Melanoma Patient Journey
Ph 1b Study of Anzu-cel (IMA203) PRAME Cell Therapy in Advanced Melanoma Patient Journey Anzutresgene autoleucel (anzu-cel, formerly IMA203), 1 Gragert et al. 2013 and census numbers; HLA-A*02:01 prevalence in Immatics’ clinical trials: US 65% and Germany 55% as of March 2025; 2 30 mg/m2 Fludarabine
Slide 13: Patients with Metastatic Melanoma in High Unmet Need Settings
Patients with Metastatic Melanoma in High Unmet Need Settings: PD-1-Relapsed Melanoma and Metastatic Uveal Melanoma a Mucosal melanoma n=2; melanoma of unknown primary n=1. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; TCR, T-cell receptor; U
Slide 14: Anzu-cel Predictable and Manageable Tolerability Profile
Anzu-cel (IMA203) PRAME Cell Therapy Demonstrated a Predictable and Manageable Tolerability Profile TEAEs in ≥30% All Melanoma (n=33) Preferred term, n (%) Any grade Grade ≥3 Nausea 22 (67) 0 ALT/AST increased 17 (52) 6 (18) Rasha 14 (42) 3 (9) Fatigue 13 (39) 0 Constipation 12 (36) 0 Hyponatremia 1
Slide 15: Anzu-cel Induced Rapid and Deep Responses
Anzu-cel (IMA203) PRAME Cell Therapy Induced Rapid and Deep Responses in Metastatic PD-1-Relapsed Melanoma and Metastatic Uveal Melanoma Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu-cel c n=14 n=16 n=3 n=33 cORRb 50% (7/14) 67% (10/15) 1/3 56% (18/32) ORR 57% (8/14) 69% (11/1
Slide 16: Anzu-cel Induced Durable Responses
Change in Sum of Longest Diameter of Target Lesions from Baseline [%] Months Post T-cell Infusion Ongoing response at 39.6 mo Response until 32.9 mo BL PR cCR cPR PR SD PD Ongoing Anzu-cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD-1-Relapsed Melanoma and Metastatic Uveal
Slide 17: Anzu-cel Durable Responses: PFS and OS
Anzu-cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD-1-Relapsed Melanoma and Metastatic Uveal Melanoma Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu-cel Median Progression Free Survival Median Overall Survival Cutaneous Melanoma n=14 Uveal Melanoma n
Slide 18: Anzu-cel in Melanoma: Overview of Studies
These data are derived from different clinical trials at different points in time with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Anzu-cel (IMA203) PRAME Cell Therapy in Melanoma:
Slide 19: Anzu-cel Enhanced mPFS of >1 Year in Deep Responders
Anzu-cel (IMA203) PRAME Cell Therapy Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses Data cut-off Sep 24, 2025 42% (14/33) patients in dose expansion have a deep response (≥50% tumor reduction) This subgroup of patients has highly medically meaningful mPFS of more than 1 year Patie
Slide 20: SUPRAME: Randomized Ph3 Trial of Anzu-cel
SUPRAME: A Randomized Ph3 Trial of Anzu-cel (IMA203) PRAME-directed TCR T-cell Therapy vs Investigator’s Choice in Unresectable or Metastatic Melanoma post ICI Actively Enrolling across North America and Europe Anzutresgene autoleucel (anzu-cel, formerly IMA203 1 Pre-specified final analysis will be
Slide 21: Cell Therapy Manufacturing Facility to Support Planned BLA
Cell Therapy Manufacturing Facility To Support Planned Anzu-cel BLA and Commercialization ~100,000 sq ft state-of-the-art research & GMP manufacturing facility Modular design for efficient and cost-effective scalability - total of 8 manufacturing suites, plus further expansion space Capacity suffici
Slide 22: Expansion to all Advanced PRAME Cancers: IMA203CD8
Expansion to all Advanced PRAME Cancers PRAME Wave #2 22 IMA203CD8 PRAME Cell Therapy
Slide 23: IMA203CD8: Expansion of Commercial Opportunity
IMA203CD8 PRAME Cell Therapy: Expansion of Commercial Opportunity to all Advanced PRAME Cancers IMA203CD8 Opportunity 2L Solid Tumors All patient numbers refer to PRAME+/HLA-A*02:01+ patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast; EU5: France, Germany, Italy, Sp
Slide 24: Towards Proof-of-concept for Tumor-agnostic Targeting with IMA203CD8
Towards Proof-of-concept for Tumor-agnostic Targeting of PRAME Cancers with IMA203CD8 Updated data across multiple PRAME-positive solid tumors are planned for presentation at the ESMO Congress 2026 AE: adverse event; cPR: confirmed partial response; RP2D: recommended phase 2 dose. Summary: IMA203CD8
Slide 25: Phase 1 Multicenter Trial of IMA203CD8
Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors PRAME Testing Biopsy or archived tissue No longer required for indications with high PRAME prevalence, including ovarian and uterine cancer IMA203CD8 Manufacturing (~2 weeks) Lymphodepletion Fludarabine 30mg/m2 Cyclophosphamide 500mg/m2 D
Slide 26: Patients Were Heavily Pretreated
Patients Were Heavily Pretreated with Limited Treatment Options n=27, includes all patients who started lymphodepletion; a Includes 1 patient with endometrial carcinoma; ADC, antibody-drug-conjugate; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; na, not
Slide 27: IMA203CD8: Safety in Gynecologic Indications
IMA203CD8: Safety in Patients with Gynecologic Indications (n=27a) Tolerability across all indications: Busse et al ESMO-IO, 2025. a Includes all patients who started lymphodepletion; b One grade 5 event at DL4a (~1.4 billion total TCR T cells) was deemed to be unlikely related to IMA203CD8 by inves
Slide 28: IMA203CD8: BOR in Gynecologic Indications
IMA203CD8: BOR in Patients with Gynecologic Indications at All DL (n=26a) Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8 * * + ≥DL4c <DL4c Baseline Tumor reduction: 78% (14/18) Evaluable patients ≥DL4c ORRb 63% (12/19) cORRc 50% (9/18) DCR (at week 6) 68% (13/19) PD Best o
Slide 29: IMA203CD8: Changes in Tumor Size Over Time
IMA203CD8: Changes in Tumor Size Over Time in Patients with Gynecologic Indications ≥DL4c (n=19a) Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8 a One patient with ovarian cancer at DL5 deceased prior to first post-BL scan non-evaluable for assessment of tumor reduction, n
Slide 30: IMA203CD8: Safety in Synovial Sarcoma
IMA203CD8: Safety in Synovial Sarcoma Data cutoff Mar 30, 2026 Araujo et al., ASCO 2026 PRAME Wave #2: IMA203CD8 a Testicular/scrotal disorders includes grouped terms; b Grade 3 CRS with transient Grade 3 hepatotoxicity improved to Grade 2 within 10 days; CRS resolved completely without need for vas
Slide 31: IMA203CD8: BOR in Synovial Sarcoma
IMA203CD8: BOR in Patients with Synovial Sarcoma (n=12) Data cutoff Mar 30, 2026 Araujo et al., ASCO 2026 PRAME Wave #2: IMA203CD8 a ORR: according to RECIST 1.1 at any post-BL scan, PD or death at any prior timepoint; cORR: according to RECIST 1.1 for patients with ≥2 post-BL scans, PD or death at
Slide 32: IMA402 PRAME Bispecific Expansion to Earlier-Line PRAME Cancers
IMA402 PRAME Bispecific Expansion to Earlier-Line PRAME Cancers PRAME Wave #3
Slide 33: IMA402: Expansion of Commercial Opportunity
IMA402 PRAME Bispecific: Expansion of the Commercial Opportunity to Earlier-Line PRAME Cancers IMA402 Opportunity 1 median half-life IMA402: ~7 days; All patient numbers refer to PRAME+/HLA-A*02:01+ patients in the US and EU5 in 2025 based on initial threshold for all indications except for sqNSCLC
Slide 34: IMA402 Phase 1 Dose Escalation Summary
Cancer Cell IMA402 PRAME Bispecific Summary: Phase 1 Dose Escalation Study Tolerability Favorable tolerability profile Most common treatment-related AEs are low-grade CRS and expected & transient lymphopenia Promising clinical activity and deep and durable responses observed at RP2D range during dos
Slide 35: Phase 1/2 Clinical Trial to Evaluate IMA402
Ph1a dose escalation completed, MTD not reached at 30 mg Provisional RP2D range identified at 10 to 30 mg Ph1b dose expansion ongoing at two distinct doses within RP2D range Combination with immune checkpoint inhibitor started Phase 1/2 Clinical Trial to Evaluate IMA402 PRAME Bispecific EudraCT No.
Slide 36: Demographics and Baseline Characteristics
Demographics and Baseline Characteristics IMA402 PRAME Bispecific 1 Efficacy-evaluable population: All patients treated as of Jun 26, 2025 (who had the opportunity for at least 3 months follow-up or who discontinued early due to disease progression or death), tested positive or not tested/not evalua
Slide 37: IMA402 Favorable Tolerability Profile
IMA402 PRAME Bispecific Shows a Favorable Tolerability Profile Safety Population (N=80) TEAEs, n (%) All Grades ≥ Grade 3 Any 78 (98) 48 (60) Treatment-related 76 (95) 42 (53) Favorable tolerability across wide dose range and consistent with tolerability at RP2D range (see appendix) Most frequent/re
Slide 38: Clinical Proof-of-Concept of IMA402 across Various Indications
Clinical Proof-of-Concept of IMA402 PRAME Bispecific across Various Indications Dose-Response Relationship in Monotherapy Setting 1 Melanoma includes cutaneous melanoma, melanoma of unknown primary, uveal melanoma; 2 Other indications include endometrioid carcinoma, synovial sarcoma and one patient
Slide 39: Deep and Durable Responses at RP2D Range
Deep and Durable Responses at RP2D Range 6/6 Confirmed Objective Responses Ongoing, incl. Two Complete Metabolic Responses at 12 mg IMA402 Complete metabolic response at 12 mg PD SD cPR Ongoing response/ disease control Ongoing treatment BOR (RECIST 1.1) All indications Melanoma Ovarian carcinoma cO
Slide 40: Early Promising PFS and OS Snapshot at RP2D Range
Early Promising PFS and OS Snapshot for IMA402 at RP2D Range Survival Outcomes Across All Indications at All Dose Levels Median PFS Median OS ≤ 1.6 mg 3 – 8 mg ≥10 mg mOS (mo) mFU (mo) 10.3 NA 13.9 12.1 Not reached 5.4 1y-OS rate 33% 63% 94% ≤ 1.6 mg 3 – 8 mg ≥10 mg mPFS (mo) mFU (mo) 1.4 NA 1.5 NA
Slide 41: Patient Case: Ongoing Complete Metabolic Response in Cutaneous Melanoma
Patient Case: Ongoing PET-based Complete Metabolic Response in Cutaneous Melanoma Patient Characteristics & Outcomes Patient & Diagnosis 68-year-old female with ICI-resistant cutaneous melanoma; initial diagnosis in 2004 Disease at Baseline Target lesions: 2 peritoneal, 1 abdominal Non-target lesion
Slide 42: IMA402 Ph1a Summary and Next Steps
IMA402 PRAME Bispecific Ph1a Dose Escalation Summary and Next Steps Expansion to Earlier-Line PRAME Cancers Promising Monotherapy & High Potential in Combination Favorable tolerability profile Deep & durable responses Promising early PFS/iPFS and OS Initial Focus Indications Development Opportunitie
Slide 43: Potential to Unlock >90% of sqNSCLC Patients with IMA401 + IMA402
Potential to Unlock >90% of sqNSCLC Patients with IMA401 + IMA402 Dual Targeting Data on file - dot plot: PRAME and MAGEA4/8 mRNA expression in stage III/IV sqNSCLC TCGA samples (TPM, log-scale), PRAME and MAGEA4/8 target prevalences are based on an optimized proprietary target expression threshold
Slide 44: IMA401 MAGEA4/8 Bispecific
IMA401 MAGEA4/8 Bispecific Maximizing the Potential of Bispecifics Combination Entering the PRAME Franchise
Slide 45: IMA401 Phase 1 Dose Escalation Summary
Cancer Cell MAGEA4/8 IMA401 MAGEA4/8 Bispecific Summary: Phase 1 Dose Escalation Study 1 at RP2D of 1-2 mg; AE: Adverse Event; CRS: Cytokine Release Syndrome; (c)ORR: (confirmed) objective response rate; DCR: disease control rate; ICI: immune checkpoint inhibitor; HNSCC: Head and neck squamous cell
Slide 46: Phase 1 Basket Trial of IMA401
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors EudraCT No 2021-004326-30; NCT05359445; a Step dosing introduced at dose levels ≥1 mg, low-dose dexamethasone partially used as preventive measure for initial doses as applied for other bispecific T-cell engagers; ability to increase dose to pr
Slide 47: IMA401 Baseline Characteristics
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors a Includes small molecule drugs and antibodies. bIMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); adNSCLC, adenocarcinoma non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; GCT, germ cell tumor;
Slide 48: Tolerability of IMA401 Monotherapy
Tolerability of IMA401 Monotherapy a All TRAEs at least possibly related to IMA401 infusion and/or pembrolizumab infusion with grade 1-2 occurring in at least 10% of all patients, all events with ≥ grade 3; b in patients with and without dexamethasone pre-medication, one possibly related death (pneu
Slide 49: Tolerability of IMA401 at RP2D ± Pembrolizumab
Tolerability of IMA401 at RP2D ± Pembrolizumab a All TRAEs at least possibly related to IMA401 infusion and/or pembrolizumab infusion with grade 1-2 occurring in at least 10% of all patients, all events with ≥ grade 3 and typical ICI-associated toxicities; b IMA401 dose in pembrolizumab expansion co
Slide 50: Efficacy of IMA401 at RP2D ± Pembrolizumab
Tolerability of IMA401 at RP2D ± Pembrolizumab Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pembrolizumab infusion in combination therapy and had a post-baseline efficacy assessment, including patients with clinical pro
Slide 51: Durable Responses to IMA401 in Patients with H&N Cancer
Durable Responses to IMA401 ± Pembrolizumab in Patients with H&N Cancer Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pembrolizumab infusion in combination therapy and had a post-baseline efficacy assessment, including p
Slide 52: Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC
Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC a Treatment start 5 weeks after last prior systemic therapy; scans courtesy of treating physician Prof. Dr. Martin Wermke, TU Dresden; BOR, best overall response; ICI, immune checkpoint inhibitor; PR, partial response; Pt, patien
Slide 53: Appendix
0Oe@ ; Immiatics Appendix Tia rANloeden
Slide 54: Anzu-cel: Shift in PFS and OS Between Dose Escalation & Expansion
Anzu-cel (IMA203): Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS of 16 Months in Melanoma Efficacy Population Progression Free Survival Data cut-off Sep 24, 2025 Overall Survival N mPFS Dose Escalation 11 2.6 months Dose Expansion 33 6.1 months N mOS
Slide 55: IMA203CD8 T-cell Persistence in Peripheral Blood
IMA203CD8 T-cell Persistence in Peripheral Blood in Multiple Indications Sustained persistence of IMA203CD8 T cells beyond 1-year post-infusion represents an important prerequisite for durable clinical benefit in all main indications evaluated Similar kinetics between indications with no significant
Slide 56: Opportunity of IMA203CD8 across PRAME+ Indications
Opportunity of IMA203CD8 across Broad Range of PRAME+ Indications Data on file; PRAME expression: evaluated biopsies (FFPE tissue) prior to treatment with anzutresgene autoleucel (anzu-cel, formerly IMA203) or IMA203CD8, melanoma: cutaneous melanoma, uveal melanoma, acral melanoma, melanoma of unkno
Slide 57: IMA203CD8 Broad Clinical Activity across PRAME+ Solid Tumors
IMA203CD8 Shows Broad Clinical Activity across Diverse PRAME+ Solid Tumors Clinical Activity in PRAME+ Tumors with Distinct Pathology / Biology Relative PRAME Expression Immunological phenotypea Clinical Activity Melanoma High Hot Uterine cancer High Mixed Synovial sarcoma / Uveal melanoma High Cold
Slide 58: Potential of PRAME-Directed Therapies in Solid Cancers
Potential of PRAME-Directed Therapies in Solid Cancers PRAME Target Expression and Prevalences in Selected Solid Cancer Types Hukelmann et al., SITC 2022, updated prevalences as of May 2025; 1 Data on file: PRAME target prevalence is based on a proprietary mass spec-guided initial expression thresho
Slide 59: Thank you
v Thank you Making a Meaningful Impact on the Lives of Patients with Cancer www.immatics.com